Korea United Pharm signs contract to supply medicines to Saudi Arabia

Its Sejong 2 anticancer drug plant received approval from the Saudi Arabian regulatory body for GMP at the beginning of this year

Korea United Pharm's Sejong 2 factory (Hankyung DB)
Korea United Pharm's Sejong 2 factory (Hankyung DB)
Jung-Eun Kim 1
2023-02-20 16:44:55 likesmile@hankyung.com
Bio & Pharma

Korea United Pharm. Inc. announced on Monday that it signed a contract to supply nine types of medicines, including 11 anticancer drugs, to Saudi pharmaceutical companies. The deal is worth $4.5 million and marks the company's effort to comply with Saudi Arabia's strengthened regulations on drug imports.

The company had previously exported the drugs to Saudi Arabia through unregistered tenders since 2012, but recently strengthened regulations prompted the company to enter into a formal supply agreement, achieving the latest result over the past month and this month.

As its Sejong 2 plant, which is dedicated to producing anticancer drugs, received approval from the Saudi Arabian regulatory body for GMP at the beginning of this year, Korea United Pharm will start full-scale production and supply to begin this year.

"We plan to choose Saudi Arabia, one of the largest pharmaceutical markets in the Middle East and Africa, as a base for entering the region and continue to seek ways to advance into other major markets in the Middle East and Africa," said an official of Korea United Pharm.

Write to Jung-Eun Kim at likesmile@hankyung.com

Humasis participates Dubai MEDLAB Middle East 2023

Humasis participates Dubai MEDLAB Middle East 2023

Humasis' booth at MEDLAB Middle East 2023 South Korean medical devices maker, Humasis Co., is participating in the MEDLAB Middle East 2023 event taking place at the Dubai World Trade Center from Feb. 6 to 9, the company said on Tuesday. The event, considered the world's largest diagnostic

South Korean biotech firms tap Middle East as next key market

South Korean biotech firms tap Middle East as next key market

NGeneBio presents its technology at Medlab between Feb. 6 and 9 South Korean biotech companies are speeding up their foray into the Middle East to tap oil money as they seek new growth engines beyond fossil fuels. NGeneBio Co., a Korean precision diagnostic platform developer, said on Monday th

Daewoong's Nabota approved for sale in Saudi Arabia, Ukraine

Daewoong's Nabota approved for sale in Saudi Arabia, Ukraine

Daewoong Pharmaceutical's botox product Nabota South Korea’s Daewoong Pharmaceutical Co. has obtained approval for the sale of its botulinum toxin product, Nabota, in Saudi Arabia and Ukraine.Saudi Arabia, one of the largest markets for botulinum toxin, more commonly known as botox, in th

(* comment hide *}